Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

1.1K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.1K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

562
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
562
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

969
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
969
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.3K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.3K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

1.2K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.2K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

1.1K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The continuous heart failure spectrum: moving beyond an ejection fraction classification.

European heart journal·2019
Same author

Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF.

Journal of cardiac failure·2019
Same author

Sex And Prognostic Significance of Self-Reported Frailty in Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From the TRILOGY ACS Trial.

The Canadian journal of cardiology·2019
Same author

Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease.

Journal of the American Heart Association·2019
Same author

Prevention of Cardiogenic Shock After Acute Myocardial Infarction.

Circulation·2018
Same author

Perspectives On The Changing Treatment Protocols of concussions in Youth Sports.

MD advisor : a journal for New Jersey medical community·2018
Same journal

Great debate: medical treatment of heart failure with reduced ejection fraction will rely on four foundational drugs.

European heart journal·2026
Same journal

The surgical collateralization theory: has the beautiful hypothesis been killed by the ugly facts?

European heart journal·2026
Same journal

Beyond single measurement: additional considerations for high-sensitivity C-reactive protein in cardiovascular risk prediction.

European heart journal·2026
Same journal

Brain mineralocorticoid receptor activation and antagonism in heart failure with preserved ejection fraction: a hypothesis.

European heart journal·2026
Same journal

Myths and misconceptions about high-sensitivity C-reactive protein as a marker of residual inflammatory risk.

European heart journal·2026
Same journal

Vascular Ehlers-Danlos syndrome: should we treat asymptomatic patients?

European heart journal·2026
See all related articles

Related Experiment Video

Updated: Nov 22, 2025

Analyzing Long-Term Electrocardiography Recordings to Detect Arrhythmias in Mice
06:07

Analyzing Long-Term Electrocardiography Recordings to Detect Arrhythmias in Mice

Published on: May 23, 2021

4.1K

Learning whether to subtract beta-blockers: it's about time.

Sean van Diepen1,2,3, Paul W Armstrong1,2

  • 1Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada.

European Heart Journal
|January 11, 2021
PubMed
Summary
This summary is machine-generated.

This study proposes a framework for secondary prevention therapy in low-risk post-myocardial infarction (MI) patients. It distinguishes between foundational therapies for all and provisional therapies for selected patients, guiding long-term treatment strategies.

More Related Videos

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis
08:05

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis

Published on: May 19, 2021

3.9K
Optical Mapping of Action Potentials and Calcium Transients in the Mouse Heart
08:13

Optical Mapping of Action Potentials and Calcium Transients in the Mouse Heart

Published on: September 13, 2011

27.8K

Related Experiment Videos

Last Updated: Nov 22, 2025

Analyzing Long-Term Electrocardiography Recordings to Detect Arrhythmias in Mice
06:07

Analyzing Long-Term Electrocardiography Recordings to Detect Arrhythmias in Mice

Published on: May 23, 2021

4.1K
Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis
08:05

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis

Published on: May 19, 2021

3.9K
Optical Mapping of Action Potentials and Calcium Transients in the Mouse Heart
08:13

Optical Mapping of Action Potentials and Calcium Transients in the Mouse Heart

Published on: September 13, 2011

27.8K

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Secondary prevention post-myocardial infarction (MI) requires tailored therapeutic strategies.
  • Current guidelines may not fully address the temporal evolution of risk in low-risk patients.

Discussion:

  • A novel framework is proposed for foundational and provisional secondary prevention therapies.
  • Foundational therapies are recommended for all patients without contraindications.
  • Provisional therapies are suggested for patients with comorbidities or post-MI complications.

Key Insights:

  • The framework incorporates a time axis for therapy duration and reassessment.
  • It emphasizes responsiveness to evolving post-MI risk and events.
  • Recommendations are pending guideline updates.

Outlook:

  • This framework aims to optimize long-term pharmacotherapeutic management in post-MI patients.
  • Future research should validate this approach in diverse patient populations.
  • Integration into clinical practice could improve secondary prevention outcomes.